PathXL, a Queen’s University Belfast firm developing digital pathology technology, is to create 32 jobs over the next three years.
The firm, which is investing £3.6m into job creation, is looking to drive the expansion of the Northern Ireland-based company with increased sales of its TissueMark software, designed to detect tumours.
Des Speed, PathXL’s CEO, said: “Our ultimate aim is to become world famous for contributing something really meaningful to the field of digital pathology. This investment will help us to further develop the new TissueMark automated tumour detection, analysis and identification solution and broaden the exposure of, and interest in, our digital pathology solution concepts.”
